STOCKSCOPE

Pro Medicus (ASX: PME) Secures $67 Million in US Hospital Deals as Its Global Growth Story Gains Momentum

Danny Aad

Danny Aad

Technology & Biotechnology Specialist | StockScope

Published:1d ago
Pro Medicus (ASX: PME) Secures $67 Million in US Hospital Deals as Its Global Growth Story Gains Momentum

Pro Medicus Limited (ASX: PME) is strengthening its position in the US healthcare technology market, with two major hospital contracts worth a combined $67 million adding to an already impressive growth pipeline.

The agreements highlight growing demand for its Visage medical imaging technology and reinforce the company's ability to secure long-term relationships with major healthcare networks.

With exceptional operating margins, strong cash generation and substantial opportunities for further expansion, Pro Medicus is building a business whose long-term earnings potential extends beyond its latest contract wins.

Key Numbers

  • $67 million: Combined minimum value of two seven-year US hospital contracts announced in October 2026.
  • $261.7 million: FY26 revenue, up 22.9%.
  • $144.7 million: FY26 underlying net profit after tax, increasing 24.1%.
  • 74.9%: FY26 underlying EBIT margin, demonstrating exceptional operating efficiency.
  • $252.3 million: Cash, term deposits and other financial assets at 30 June 2026, with no debt.

Latest Development: US Expansion Builds Further Momentum

Pro Medicus secured a seven-year, $43 million agreement with New Jersey-based Virtua Health on 21 October 2026, following a $24 million agreement with Billings Clinic–Logan Health in Montana on 19 October.

Both agreements expand the adoption of its Visage medical imaging technology across American healthcare networks.

The contracts build on a strong FY26 performance, during which Pro Medicus secured 10 new agreements worth at least $407 million and renewed six existing contracts valued at $141 million.

Importantly, these long-term commitments provide greater visibility over future revenue opportunities.

The latest $67 million represents minimum contracted value across seven years rather than immediate revenue. An even annual allocation would represent approximately $9.6 million, although actual contributions depend on implementation schedules and contractual arrangements.

As deployments progress, these agreements could provide another meaningful source of recurring revenue.

What Stands Out to Us: A Highly Profitable Growth Model

Pro Medicus has established a differentiated position through its Visage imaging platform, which enables healthcare providers to manage and interpret increasingly complex medical images.

Its competitive strengths include proprietary technology, long-term hospital relationships and significant switching costs associated with replacing critical clinical software.

The company's financial performance demonstrates the effectiveness of this model.

FY26 underlying EBIT reached $196.1 million, delivering an impressive 74.9% margin.

Operating cash inflows totalled approximately $127.5 million, reinforcing the business's capacity to generate cash while continuing to expand.

Although reported profit of $265.3 million included substantial unrealised financial asset valuation gains, underlying earnings provide a clearer indication of recurring operating performance.

At approximately $20.1 billion in equity value based on its 19 November 2026 closing share price, Pro Medicus commands a substantial valuation premium.

We believe its combination of profitability, recurring revenue opportunities and established competitive advantages helps explain that premium, although continued earnings growth will be essential to sustaining it.

What the Company Is Doing Now

Pro Medicus continues expanding its US hospital presence while developing additional opportunities in cardiology, digital pathology and AI-optimised reporting.

During FY26, the company completed 16 implementations, including deployments across Trinity Health.

Management expects these implementations to contribute more substantially during FY27.

Beyond securing new customers, a significant opportunity lies in expanding the use of Visage technology across existing healthcare networks.

Broader clinical adoption could increase revenue per customer while allowing Pro Medicus to capitalise on its established software infrastructure.

Insight: Could Pro Medicus Have More Growth Ahead?

We see Pro Medicus as a high-quality healthcare technology business with several compelling long-term growth drivers. Its exceptional margins, established hospital relationships and debt-free balance sheet provide a strong foundation for continued expansion. What particularly stands out is the potential to increase revenue from existing healthcare networks as additional imaging applications gain traction. While its premium valuation requires sustained earnings growth, the company's financial strength and expanding contract portfolio provide credible support for its commercial ambitions. Implementation progress and cash conversion remain important measures of success.

What Happens Next?

The company's annual general meeting on 25 November 2026 represents the next scheduled corporate milestone, followed by its FY27 half-year results.

Key indicators include implementation progress, additional hospital contracts, underlying earnings growth and operating cash conversion.

With an expanding US footprint and opportunities to extend its technology into additional clinical applications, Pro Medicus has several potential avenues for continued growth.

The next phase will reveal how effectively its growing contract portfolio translates into higher recurring revenue, profitability and long-term cash generation.

Danny Aad

Danny Aad

(Technology & Biotechnology Specialist | StockScope)

Danny Aad is an experienced technology executive with a distinguished career spanning more than three decades, including senior leadership positions as Chief Technology Officer (CTO) across the technology and biotechnology sectors. With extensive expertise in technology strategy, digital innovation and the evolving biotechnology landscape, Danny brings a wealth of industry knowledge and technical insight to his analysis of emerging technologies, corporate developments and investment opportunities.

DisclaimerInformation on Stockscope is general in nature and does not constitute financial product advice. It does not take into account your personal objectives, financial situation or needs. Seek independent advice from a qualified financial adviser before making an investment decision. Stockscope and its affiliates do not guarantee the accuracy or completeness of information published on this website. To the extent permitted by law, they accept no liability for any claim, loss or damage arising from its use or reliance on it. Stockscope and its associates may have commercial relationships with companies featured on this website, hold securities in those companies, or receive commissions in connection with capital raisings.

Continue Reading

ASX slides to five-month low as AI sell-off rattles global markets
Market Briefings
Market Briefings

ASX slides to five-month low as AI sell-off rattles global markets

Australian equities: what moved the ASX 200? Australian shares extended their losing streak on Friday, with the S&P/ASX 200 falling 137.8 points, or 1.58%, to close at 8,592.6. This marked...

Mark ElzayedMark Elzayed•
NEXTDC (ASX: NXT) Raises FY27 Earnings Outlook as $140 Million Melbourne Opportunity Remains in Play
Technology
Technology

NEXTDC (ASX: NXT) Raises FY27 Earnings Outlook as $140 Million Melbourne Opportunity Remains in Play

NEXTDC Limited ASX: NXT has delivered an encouraging upgrade to its FY27 earnings guidance, highlighting the strength of its broader data centre business despite electricity supply delays at...

Danny AadDanny Aad•
Trek Metals (ASX: TKM) Hits 40.3% Manganese at Kuro as High-Grade Discovery Opens Up Bigger Potential
Mining
Mining

Trek Metals (ASX: TKM) Hits 40.3% Manganese at Kuro as High-Grade Discovery Opens Up Bigger Potential

A standout 25-metre intersection grading 31.4% manganese has delivered another encouraging result for Trek Metals Limited ASX: TKM, strengthening the exploration potential of its Kuro discov...

Alison ElzayedAlison Elzayed•
EBR Systems (ASX: EBR) Moves Closer to US-Wide Medicare Coverage as Major Growth Opportunity Emerges
Biotech & Health
Biotech & Health

EBR Systems (ASX: EBR) Moves Closer to US-Wide Medicare Coverage as Major Growth Opportunity Emerges

EBR Systems ASX: EBR has taken another significant step towards expanding the commercial reach of its wireless heart pacing technology, with US Medicare authorities proposing national covera...

Danny AadDanny Aad•
Orion Minerals (ASX: ORN) Unlocks US$6.7 Million From Glencore as Major Copper Production Milestone Approaches
Mining
Mining

Orion Minerals (ASX: ORN) Unlocks US$6.7 Million From Glencore as Major Copper Production Milestone Approaches

Orion Minerals ASX: ORN has reached a significant turning point in its copper and zinc development strategy, receiving its first US$6.7 million payment from global mining group Glencore. The...

Alison ElzayedAlison Elzayed•
EMVision Medical Devices (ASX: EMV) Unlocks a 1,700-Hospital Opportunity as Fresh Funding Accelerates Stroke Scanner Development
Biotech & Health
Biotech & Health

EMVision Medical Devices (ASX: EMV) Unlocks a 1,700-Hospital Opportunity as Fresh Funding Accelerates Stroke Scanner Development

EMVision Medical Devices ASX: EMV is building momentum towards a potentially significant commercial breakthrough, with a fresh $306,750 government grant payment supporting the expansion of i...

Danny AadDanny Aad•
Loading more stories...